Anglo French Annual Reports, Balance Sheet and Financials

Anglo French Drugs and Industries Limited Balance Sheet (Rs in Lakhs)

Anglo French Drugs and Industries Limited Profit & Loss Statement (Rs in Lakhs)

Anglo French Drugs and Industries Limited Consolidated Cash Flow Statement (Rs in Lakhs)

Here is the analysis of cash flow for year March 2024 and 2023:

Profit before tax: In the financial year ending March 31st, 2024, the company reported a loss before tax amounting to -1,229 units (currency unspecified), a significant decrease from the profit before tax of 25,108 units reported in the previous year, March 31st, 2023. This decrease indicates a downturn in profitability year-over-year.

Adjustments for depreciation and amortization: Depreciation and amortization expenses totaled 315 units in 2024, slightly lower than the 334 units recorded in 2023. These adjustments reflect the non-cash expenses related to the wear and tear of assets over time.

Interest expense and income: The company paid 185 units in interest expenses in 2024, compared to 307 units in 2023, indicating a decrease in interest costs. Conversely, interest income showed a reduction from -344 units in 2023 to -240 units in 2024, potentially due to lower interest earnings on investments.

Provisions written back and gains/losses on investments: There were no provisions written back in either year. However, the company recorded a loss of -126 units on investments in 2024, whereas no such loss was reported in 2023. This reflects a negative impact on earnings from investments.

Dividend income: Dividend income decreased from -45 units in 2023 to -28 units in 2024, indicating lower dividend earnings for the company.

Operating profit before working capital changes: The operating profit before adjustments for changes in working capital was -1,125 units in 2024, significantly lower than the 25,338 units reported in 2023. This substantial decrease reflects the overall decline in operating profitability.

Changes in working capital: There were several adjustments in working capital components:

Trade receivables increased by 1,733 units in 2024, compared to a decrease of -2,534 units in 2023.

Inventories decreased by -294 units in 2024, following an increase of 2,374 units in 2023.

Current financial assets decreased by -633 units in 2024, compared to a decrease of -348 units in 2023.

Non-current financial assets increased by 86 units in 2024, whereas no change was reported in 2023.

Other current assets increased by 101 units in 2024, compared to an increase of 135 units in 2023.

Trade payables increased by 152 units in 2024, following a decrease of -313 units in 2023.

Current financial liabilities increased by 187 units in 2024, whereas they decreased by -177 units in 2023.

Non-current financial liabilities decreased by -52 units in 2024, with no change reported in 2023.

Other current liabilities did not change in 2024, while they increased by 35 units in 2023.

Other non-current liabilities decreased by -303 units in 2024, with no change reported in 2023.

Cash generated from operations: The net cash flow from operating activities before exceptional items was -6 units in 2024, compared to 18,471 units in 2023. This significant decrease indicates a substantial decline in cash generated from core operational activities.

Cash flow from investing activities: The company invested 4,136 units in various activities in 2024, primarily driven by payments for acquisition of assets and investments, compared to a cash outflow of -17,040 units in 2023. This shift reflects a strategic redirection of investment priorities.

Cash flow from financing activities: Financing activities in 2024 resulted in a net cash outflow of -4,406 units, compared to -1,170 units in 2023. This increase in outflow was due to changes in long-term and short-term borrowings, buyback of shares, and dividend payments.

Net cash inflow/outflow: Overall, the company experienced a net cash outflow of -276 units in 2024, contrasting with a net inflow of 261 units in 2023. This change underscores the company 's cash management challenges and strategic financial decisions over the year.

Opening and closing cash and cash equivalents: The period started with 284 units of cash and cash equivalents in 2024, increased to 284 units by the end of the period. In contrast, 2024 saw a decrease from 23 units to 9 units.

Statement of Financial results for the Quarter Ended 30^th June 2024 (Rs. in Lakhs)

Financial Ratios of Anglo French Drugs and Industries Limited

Here is the summary of financial and operational metrics for Anglo French Drugs And Industries Limited for year 2024 & 2023:

Current Ratio:

2024: 5.45

2023: 6.48

Insight: The current ratio measures the company 's ability to meet its short-term obligations with its short-term assets. A decrease from 6.48 in 2023 to 5.45 in 2024 indicates a slight reduction in liquidity. However, both ratios are comfortably above 1, indicating a strong ability to cover short-term liabilities.

Debt Equity Ratio:

2024: 0.05

2023: 0.12

Insight: The debt equity ratio measures the proportion of debt and equity financing used by the company. A decrease from 0.12 in 2023 to 0.05 in 2024 suggests a reduction in reliance on debt financing relative to equity, indicating potentially improved financial stability.

Debt Service Coverage Ratio:

2024: (-5.14)

2023: 104.97

Insight: The debt service coverage ratio assesses the company 's ability to cover its debt obligations with its operating income. A negative ratio in 2024 (-5.14) indicates that the company 's operating income was insufficient to cover its debt servicing obligations during that period. This is a significant decline from a very strong coverage ratio of 104.97 in 2023, suggesting increased financial strain.

Return on Equity Ratio:

2024: (-0.02)

2023: 0.42

Insight: The return on equity (ROE) ratio measures how effectively the company generates profits from shareholders ' equity. A negative ROE in 2024 (-0.02) indicates a loss during the period, contrasting with a positive ROE of 0.42 in 2023. This reflects a decrease in profitability and potential financial challenges.

Inventory Turnover (no of days):

2024: 0.15

2023: 0.31

Insight: The inventory turnover ratio measures how efficiently the company manages its inventory. A decrease from 0.31 days in 2023 to 0.15 days in 2024 suggests that the company is holding onto inventory for fewer days, indicating potentially improved inventory management efficiency.

Debtors Turnover Ratio:

2024: 0.53

2023: 0.45

Insight: The debtors turnover ratio measures how efficiently the company collects payments from its customers. An increase from 0.45 in 2023 to 0.53 in 2024 indicates improved efficiency in collecting receivables.

Payables Turnover Ratio:

2024: 0.28

2023: 0.31

Insight: The payables turnover ratio measures how quickly the company pays its suppliers. A slight decrease from 0.31 in 2023 to 0.28 in 2024 suggests a slight increase in the time taken to pay suppliers, which could be indicative of changing payment terms or business conditions.

Net Capital Turnover:

2024: 0.60

2023: 0.49

Insight: The net capital turnover ratio measures how effectively the company utilizes its capital to generate revenue. An increase from 0.49 in 2023 to 0.60 in 2024 indicates improved efficiency in capital utilization and revenue generation.

Net Profit Margin (%):

2024: −0.13-0.13%−0.13

2023: 1.73%

Insight: The net profit margin measures the percentage of revenue that translates into profit after all expenses. A negative net profit margin in 2024 (-0.13%) indicates a loss, contrasting with a positive net profit margin of 1.73% in 2023. This reflects a decline in profitability and financial performance.

Dividend History

Anglo French Drugs And Industries Limited Recent Financial Performance:

Dividend per Share: The specific dividend per share figure for March 2024 is Rs. 1.50 and 2023 is not provided; Dividend per share represents the portion of a company 's earnings that is distributed to shareholders in the form of dividends. A higher dividend per share may indicate that the company is sharing more of its profits with shareholders.

Retained Earnings: Retained earnings for 2024 amounted to Rs. 16,088 Lakhs, while in 2023, they were Rs. 19,868 Lakhs. Retained earnings represent the portion of a company 's profits that is reinvested in the business rather than distributed as dividends. An increase in retained earnings suggests that the company has retained more of its profits for reinvestment or future growth.

To provide a more comprehensive analysis, it would be necessary to consider additional financial metrics such as revenue, net profit, assets, liabilities, and cash flows. Additionally, an analysis of trends over multiple years and a comparison to industry benchmarks and competitors would help in assessing the company 's financial health and performance.